Related references
Note: Only part of the references are listed.Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations Diagnostic and Clinical Implications
Athanasios C. Tsiatis et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
K. -L. Garm Spindler et al.
ANNALS OF ONCOLOGY (2009)
Fast simultaneous detection of K-RAS mutations in colorectal cancer
Ya-Sian Chang et al.
BMC CANCER (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Implementation of Novel Pyrosequencing Assays to Screen for Common Mutations of BRAF and KRAS in a Cohort of Sporadic Colorectal Cancers
Deborah Packham et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting
Vicki Whitehall et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples
Zhuang Zuo et al.
MODERN PATHOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
Vassiliki Kotoula et al.
PLOS ONE (2009)
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
Jens Neumann et al.
PATHOLOGY RESEARCH AND PRACTICE (2009)
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer:: Primary or secondary genetic events in colorectal carcinogenesis?
Sergia Velho et al.
BMC CANCER (2008)
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
Anthony Goncalves et al.
BMC CANCER (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
K-ras mutation detection in colorectal cancer using the Pyrosequencing technique
Angela Poehlmann et al.
PATHOLOGY RESEARCH AND PRACTICE (2007)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Relationship between genetic alterations and prognosis in sporadic colorectal cancer
SC Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component
S Ogino et al.
MODERN PATHOLOGY (2006)
Exploring the tumour environment:: cancer-associated fibroblasts as targets in cancer therapy
P Micke et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Sensitive Sequencing method for KRAS mutation detection by pyrosequencing
S Ogino et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer
G Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer
S Tórtola et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
